Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Narlumosbart by CSPC Pharmaceutical Group for Giant Cell Tumor Of Bone: Likelihood of Approval
Narlumosbart is under clinical development by CSPC Pharmaceutical Group and currently in Phase III for Giant Cell Tumor Of Bone....
Data Insights
Narlumosbart by CSPC Pharmaceutical Group for Humoral Hypercalcemia of Malignancy: Likelihood of Approval
Narlumosbart is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Humoral Hypercalcemia of Malignancy. According...